Patients with severe lupus nephritis who have both diffuse proliferative (class IV) and membranous (class V) lesions on biopsy can be refractory to current monotherapy treatments. Bao et al.

the interpretation was that the low albumin and proteinuria likely represented nephrotic syndrome and that this argued for the possibility of class V lupus nephritis or the membranous lupus lesion.

[1] In previous years, randomized, controlled trials (RCTs) at the NIH and other institutions, mainly involving patients with severe lupus nephritis, have demonstrated the superiority of the ...

While Roche’s Gazyva has been on the market for a dozen years and has won four approvals from the FDA, it is making a late ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

Nat Clin Pract Nephrol. 2007;3(6):296-297. How did this transfer of 'ownership' of lupus nephritis to rheumatologists happen? There are two possible reasons. Either rheumatologists hijacked lupus ...

The Phase 1 GALLOP study evaluating investigational therapy, CB-010, for treatment of lupus nephritis (LN) has officially started. This open label, multicenter study will assess a single infusion of ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...